Technology
Health
Biotechnology

Calithera Biosciences

$5.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-1.40%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CALA and other stocks, options, ETFs, and crypto commission-free!

About

Calithera Biosciences, Inc. engages in discovering and developing small molecule drugs that that target novel and critical metabolic pathway in tumor and cance-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. Read More The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Employees
79
Headquarters
South San Francisco, California
Founded
2010
Market Cap
220.43M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
281.62K
High Today
$5.81
Low Today
$5.56
Open Price
$5.69
Volume
42.43K
52 Week High
$6.90
52 Week Low
$3.55

Collections

Technology
Health
Biotechnology
Medical
2014 IPO
US
North America
Female CEOs

News

Seeking AlphaMay 9

Calithera Biosciences, Inc. CEO Susan Molineaux on Q1 2019 Results - Earnings Call Transcript

Calithera Biosciences, Inc. (NASDAQ:CALA) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Jennifer McNealey - Vice President of Investor Relations and Strategy Susan Molineaux - Founder, President, Chief Executive Officer Keith Orford - Chief Medical Officer Stephanie Wong - Senior Vice President of Finance and Secretary Conference Call Participants John Barrett - SVB Leerink Matt Phipps - William Blair Operator Hello and welcome to the Calithera Biosciences Q1...

22
Yahoo FinanceMay 9

Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019-- SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways, announced today its financial results for the first quarter ended March 31, 2019. As of March 31, 2019, cash equivalents and investments totaled $117.0 million...

5
Markets InsiderMay 3

Calithera Biosciences to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

24

Earnings

-$0.61
-$0.44
-$0.26
-$0.09
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.44 per share
Actual
-$0.61 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.